Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
FENC Fennec Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: FENC
Price (delayed)
$7.675
Market cap
$211.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.53
Enterprise value
$207.38M
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation
Highlights
FENC's debt is down by 39% year-on-year
The gross profit has contracted by 37% from the previous quarter and by 35% YoY
FENC's revenue is down by 35% from the previous quarter and by 31% YoY
Key stats
What are the main financial stats of FENC
Market
Valuations
Earnings
Shares outstanding
27.62M
Market cap
$211.97M
Enterprise value
$207.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
6.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.71
Revenue
$30.91M
Gross profit
$27.91M
Operating income
-$11.98M
Net income
-$14.44M
EBIT
-$10.45M
EBITDA
-$11.14M
Free cash flow
-$16.39M
Per share
Balance sheet
Liquidity
EPS
-$0.53
EPS diluted
-$0.53
Free cash flow per share
-$0.59
Book value per share
-$0.21
Revenue per share
$1.12
TBVPS
$1.68
Total assets
$46.4M
Total liabilities
$52.28M
Debt
$18.08M
Equity
-$5.88M
Working capital
$34.6M
Debt to equity
-3.07
Current ratio
5.13
Quick ratio
4.87
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
-36%
Gross margin
90.3%
Net margin
-46.7%
Operating margin
-38.8%
Return on assets
-27.1%
Return on equity
N/A
Return on invested capital
-28.6%
Return on capital employed
-27.5%
Return on sales
-33.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FENC stock price
How has the Fennec Pharmaceuticals stock price performed over time
Intraday
-2.54%
1 week
-5.48%
1 month
21.83%
1 year
14.9%
YTD
21.44%
QTD
26.03%
Financial performance
How have Fennec Pharmaceuticals's revenue and profit performed over time
Revenue
$30.91M
Gross profit
$27.91M
Operating income
-$11.98M
Net income
-$14.44M
Gross margin
90.3%
Net margin
-46.7%
The gross profit has contracted by 37% from the previous quarter and by 35% YoY
FENC's revenue is down by 35% from the previous quarter and by 31% YoY
The gross margin has contracted by 6% YoY and by 3.2% from the previous quarter
Price vs fundamentals
How does FENC's price correlate with its fundamentals
Growth
What is Fennec Pharmaceuticals's growth rate over time
Valuation
What is Fennec Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
6.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.71
The P/S is 80% higher than the last 4 quarters average of 3.8
FENC's revenue is down by 35% from the previous quarter and by 31% YoY
Efficiency
How efficient is Fennec Pharmaceuticals business performance
Dividends
What is FENC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FENC.
Financial health
How did Fennec Pharmaceuticals financials performed over time
The total assets is 11% less than the total liabilities
The total assets has contracted by 33% YoY but it has grown by 3.2% from the previous quarter
FENC's current ratio is down by 26% year-on-year and by 20% since the previous quarter
The company's debt to equity has shrunk by 131% YoY
FENC's debt is down by 39% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.